Dr. Ernest S. Weeks JR., M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 449
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MS license 20530
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Billings Clinic Hospital Billings, MT
- Mississippi Baptist Medical Center Jackson, MS
- St Dominic-Jackson Memorial Hospital Jackson, MS
- Merit Health River Oaks Flowood, MS
- Baptist Medical Center-Leake Carthage, MS
Medical groups
- Billings Clinic Specialty Supplies and Services, LLC (824 clinicians)
- St. Dominic Medical Associates LLC (132 clinicians)
- Gastrointestinal Associates PA (46 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 449
- Services billed
- 13,405
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, vedolizumab, 1 mg | 6,030 | 11 |
| Injection, infliximab, excludes biosimilar, 10 mg | 2,896 | 20 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 733 | 64 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 412 | 65 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 140 | 136 |
| Established patient office or other outpatient visit, 30-39 minutes | 116 | 90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 107 | 105 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 96 | 67 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 89 | 16 |
| Biopsy of large bowel using a flexible endoscope | 87 | 87 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Flowood, MS | 328 |
| Pantoprazole Sodium Other prescribers in Flowood, MS | 135 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Flowood, MS | 92 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 70 |
| Sucralfate Other prescribers in Flowood, MS | 55 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Flowood, MS | 44 |
| Dicyclomine Hcl Other prescribers in Flowood, MS | 43 |
| Linzess (linaclotide) Other prescribers in Flowood, MS | 38 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 29 |
| Famotidine Other prescribers in Flowood, MS | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 18 payments worth $372 in total to this clinician.
| Phathom Pharmaceuticals, Inc. | $105 |
|---|---|
| AbbVie Inc. | $87.03 |
| Takeda Pharmaceuticals U.S.A., Inc. | $68.73 |
| Ipsen Biopharmaceuticals, Inc | $31.22 |
| Genzyme Corporation | $22.64 |
| Aimmune Therapeutics, Inc. | $20.95 |
| Regeneron Healthcare Solutions, Inc. | $20.58 |
| Intercept Pharmaceuticals, Inc. | $15.61 |
| Food and Beverage | $372 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $48,489 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie Inc. · Active, not recruiting · NCT06880744 - Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)
Bausch Health US, LLC - A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.